US Treasury floats China biotech investment limits, with licensing deals exempted
- The US government released a proposal treating US investment in Chinese biotech as a national security matter, implementing the COINS Act.
- Per the headline, licensing deals are exempted; Endpoints separately describes sharp limits on US investment in much of China biotech.
- Industry leaders responded cautiously, saying innovation should not be stifled.
💡 Points
The licensing carve-out is the part that matters: China-sourced assets remain buyable, so the in-licensing pipeline that big pharma has leaned on likely keeps running. What gets squeezed is US equity capital, which could push Chinese biotechs toward Hong Kong, domestic or Middle Eastern funding. Details are still thin, so scope and definitions will decide the real impact.
US explores China biotech restrictions, exempts licensing deals ↗